Kasumi-1 Xenograft Model Service for AML

The Kasumi-1 cell line, established from a human acute myeloid leukemia (AML) patient harboring the characteristic t(8;21) chromosome translocation, provides a premier, molecularly defined in vivo translational platform for assessing the therapeutic potential of novel targeted therapies and conventional antileukemic agents. As a specialized pre-clinical contract research organization, Alfa Cytology offers a highly optimized, turnkey Kasumi-1 Xenograft Model Service that couples rigorous cellular quality control with standardized systemic inoculation protocols to accelerate your hematological oncology pipelines.

Overview of Kasumi-1 Xenograft Model for AML

The Kasumi-1 xenograft model stands as an invaluable and genetically precise in vivo translational tool extensively utilized in hematological malignancy research, specifically for studying AML subtypes characterized by the RUNX1-RUNX1T1 (formerly AML1-ETO) fusion gene. By transplanting human Kasumi-1 myeloblastoid cells into optimized immunodeficient mouse hosts, this model successfully recapitulates systemic disease progression, targeted bone marrow homing kinetics, and peripheral blood pathophysiological profiles that align with human clinical leukemic development.

Biologically, the Kasumi-1 model exhibits reliable systemic engraftment parameters and reproducible expansion kinetics, presenting preclinical researchers with a stable experimental window required for executing rigid therapeutic screening and multi-dose regimens. This platform uniquely preserves critical human myeloid signatures, including the native expression of fusion transcripts, altered tyrosine kinase signaling pathways, and specific cell-surface differentiation antigens. Because of these distinct molecular and genetic hallmarks, the Kasumi-1 model is widely deployed across global drug discovery programs to evaluate the anti-leukemic potency of novel small-molecule core-binding factor inhibitors, targeted monoclonal antibodies, epigenetic modulators, and combination systemic chemotherapy regimens.

Fig 1. Chemosensitizing effects of type I IFN in human AML xenografts. (Holicek, P., et al., 2023)

Cell Line Information: Kasumi-1

The Kasumi-1 cell line was originally established from the peripheral blood of a 7-year-old male Japanese AML patient at relapse. Growing as suspension cultures under standard in vitro laboratory parameters, these cells retain a stable myeloblastoid phenotype and serve as a cornerstone genetic model for t(8;21)-positive hematological oncology research.

Our Services

Workflow of Kasumi-1 Xenograft Model Construction

• Cell Culture & Quality Control: Human Kasumi-1 cells are expanded in vitro using certified nutrient suspension media under optimized environmental parameters. STR profiling and mycoplasma clearance verification are mandatory prior to harvesting to ensure absolute biological purity and phenotypic identity.
• Host Selection & Acclimatization: Standardized, healthy immunodeficient mice (highly permissive strains such as NSG or NOD/SCID to support hematological engraftment) are sourced from validated vendors. The animals undergo a dedicated acclimatization phase within a controlled facility to establish stable baseline biological metrics.
• Precision Inoculation: A calibrated suspension of high-viability Kasumi-1 cells is prepared in a sterile physiological buffer. The cellular suspension is precisely inoculated in vivo into host cohorts via tail vein intravenous routes to facilitate systemic leukemic distribution.
• Longitudinal Growth Tracking: Following inoculation, leukemic progression is systematically monitored using FACS to detect human CD45+ cells or specific myeloid markers in peripheral blood samples. Animal body weights, physical baselines, and clinical symptoms of leukemic burden are routinely cataloged.
• Stratification & Dosing: Once peripheral leukemic chimerism reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts. This stratification step ensures balanced baseline systemic dimensions across all groups before customized therapeutic dosing regimens commence.

Fig 2. Kasumi-1 Xenograft Model Construction Workflow

Case Study - Kasumi-1 Xenograft Model Development

A preclinical validation study was conducted utilizing the Kasumi-1 xenograft model to evaluate the therapeutic efficacy of a novel small-molecule inhibitor targeting core-binding factor leukemia pathways. Following precision intravenous inoculation of human Kasumi-1 cells into immunodeficient mice, the animals demonstrated steady, systemic leukemic engraftment and a highly predictable disease progression across the study cohorts. Animals assigned to the active treatment group exhibited a clear, statistically significant reduction in circulating leukemic blasts and prolonged survival times compared to the vehicle control group, confirming the model's high sensitivity and robust predictive reliability for screening targeted AML therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Specialized knowledge in the cultivation and maintenance of diverse squamous cell carcinoma lineages, providing reliable in vivo platforms for complex AML studies.
• Rigorous Quality Control: Stringent validation at every phase of in vitro and in vivo processing to completely eliminate confounding biological variables.
• Tailored Experimental Design: Flexible study frameworks accommodating custom mouse strain choices, specific dosing routes, and orthotopic or subcutaneous inoculation pathways.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready data report providing comprehensive digital caliper metrics and robust statistical validations.

Contact us

Accelerating your AML pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing utilizing our Kasumi-1 platform, please reach out to us today to discuss your project layout with our scientific team.

For research use only. Not intended for any clinical use.